Major Advancements in Metastatic Breast Cancer Treatment: when Expanding Options Means Prolonging Survival

Overview

Journal ESMO Open

Publisher Elsevier

Specialty Oncology

Date 2022 Mar 1

PMID 35227965

Authors

F Miglietta

M Bottosso

G Griguolo

M V Dieci

V Guarneri

Affiliations

Soon will be listed here.

Abstract

In the last years we have witnessed tremendous advancements in the treatment landscape of metastatic breast cancer (MBC), leading to a progressive prolongation of progression-free survival and, in some cases, also of overall survival. This led to a substantial increase of advanced disease treatability. In the present review we comprehensively and critically describe the most significant progresses in the therapeutic scenario of MBC according to BC subtype. In particular, we reviewed studies reporting practice-changing data in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative, HER2-positive and triple-negative BC, with also a hint to BRCA-related tumors and the emerging HER2-low-positive category.

Citing Articles

Temporal evolution of breast cancer brain metastases treatments and outcomes.

Bottosso M, Griguolo G, Guiu S, Guarascio M, Bailleux C, Miglietta F NPJ Breast Cancer. 2025; 11(1):20.

PMID: 39979277 PMC: 11842824. DOI: 10.1038/s41523-025-00735-w.

Returning to work after breast cancer: a longitudinal analysis of employment and financial hardship.

Park E, Peterson L, McKeon S, Fiala M Breast Cancer Res Treat. 2025; .

PMID: 39894861 DOI: 10.1007/s10549-025-07624-7.

Liposomal Formulation of Hydroxychloroquine Can Inhibit Autophagy In Vivo.

Dragowska W, Singh J, Wehbe M, Anantha M, Edwards K, Gorski S Pharmaceutics. 2025; 17(1).

PMID: 39861690 PMC: 11768354. DOI: 10.3390/pharmaceutics17010042.

Atherosclerosis and the Bidirectional Relationship Between Cancer and Cardiovascular Disease: From Bench to Bedside, Part 2 Management.

Gallucci G, Larocca M, Navazio A, Turazza F, Inno A, Canale M Int J Mol Sci. 2025; 26(1.

PMID: 39796190 PMC: 11719480. DOI: 10.3390/ijms26010334.

Analysis of the Effects of Different Chemotherapy Methods on Blood Lipid Levels in Breast Cancer Patients.

Mu J, Zhou M, Jiao G Breast Cancer (Dove Med Press). 2024; 16:745-760.

PMID: 39553240 PMC: 11566600. DOI: 10.2147/BCTT.S456422.

References

Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q . Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021; 22(3):351-360. DOI: 10.1016/S1470-2045(20)30702-6. View

Lewis Phillips G, Li G, Dugger D, Crocker L, Parsons K, Mai E . Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008; 68(22):9280-90. DOI: 10.1158/0008-5472.CAN-08-1776. View

Baselga J, Im S, Iwata H, Cortes J, De Laurentiis M, Jiang Z . Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(7):904-916. PMC: 5549667. DOI: 10.1016/S1470-2045(17)30376-5. View

Kurian A, Gong G, John E, Miron A, Felberg A, Phipps A . Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev. 2009; 18(4):1084-91. PMC: 2706699. DOI: 10.1158/1055-9965.EPI-08-1090. View

Modi S, Saura C, Yamashita T, Park Y, Kim S, Tamura K . Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2019; 382(7):610-621. PMC: 7458671. DOI: 10.1056/NEJMoa1914510. View

Gennari A, Andre F, Barrios C, Cortes J, de Azambuja E, DeMichele A . ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021; 32(12):1475-1495. DOI: 10.1016/j.annonc.2021.09.019. View

Pivot X, Marme F, Koenigsberg R, Guo M, Berrak E, Wolfer A . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol. 2016; 27(8):1525-31. PMC: 4959925. DOI: 10.1093/annonc/mdw203. View

Murthy R, Borges V, Conlin A, Chaves J, Chamberlain M, Gray T . Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018; 19(7):880-888. DOI: 10.1016/S1470-2045(18)30256-0. View

Bardia A, Kaklamani V, Wilks S, Weise A, Richards D, Harb W . Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. J Clin Oncol. 2021; 39(12):1360-1370. PMC: 8078341. DOI: 10.1200/JCO.20.02272. View

10.

OLeary B, Cutts R, Huang X, Hrebien S, Liu Y, Andre F . Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. J Natl Cancer Inst. 2020; 113(3):309-317. PMC: 7936069. DOI: 10.1093/jnci/djaa087. View

11.

Emens L, Molinero L, Loi S, Rugo H, Schneeweiss A, Dieras V . Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. J Natl Cancer Inst. 2021; 113(8):1005-1016. PMC: 8328980. DOI: 10.1093/jnci/djab004. View

12.

Sledge Jr G, Toi M, Neven P, Sohn J, Inoue K, Pivot X . The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2019; 6(1):116-124. PMC: 6777264. DOI: 10.1001/jamaoncol.2019.4782. View

13.

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

14.

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

15.

Brufsky A, Valero V, Tiangco B, Dakhil S, Brize A, Rugo H . Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat. 2012; 133(3):1067-75. DOI: 10.1007/s10549-012-2008-6. View

16.

Lord C, Ashworth A . PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158. PMC: 6175050. DOI: 10.1126/science.aam7344. View

17.

Bardia A, Tolaney S, Punie K, Loirat D, Oliveira M, Kalinsky K . Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021; 32(9):1148-1156. DOI: 10.1016/j.annonc.2021.06.002. View

18.

Javle M, Curtin N . The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol. 2011; 3(6):257-67. PMC: 3210467. DOI: 10.1177/1758834011417039. View

19.

Blackwell K, Burstein H, Storniolo A, Rugo H, Sledge G, Koehler M . Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010; 28(7):1124-30. DOI: 10.1200/JCO.2008.21.4437. View

20.

Helleday T . The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011; 5(4):387-93. PMC: 5528309. DOI: 10.1016/j.molonc.2011.07.001. View